Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 366

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 366
---
 quorum is present, none of the outstanding Denali Class A Ordinary Shares held by the public shareholders must be voted in favor of the Business Combination Proposal for it to be approved and, therefore, it could be approved
without any votes by any public shareholders. See the section titled “The Merger Agreement–Certain Related Agreements and Arrangements–Sponsor Support Agreement” for more information.

Resolution to be Voted Upon

The full text of the resolution to be passed is as follows:

“RESOLVED, AS AN ORDINARY RESOLUTION THAT, the transactions contemplated under the Agreement and Plan of Merger, dated as of
August 30, 2024 (as it may be amended or restated from time to time in accordance with its terms, including by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 16, 2025 (“Amendment No. 1 to Merger Agreement”) and
Amendment No. 2 to Agreement and Plan of Merger, dated as of July 22, 2025 (the “Amendment No. 2 to Merger Agreement”), the “Merger Agreement”), by and among Denali, Denali Merger Sub Inc., a Delaware corporation and wholly
owned subsidiary of Denali (“Merger Sub”), and Semnur Pharmaceuticals, Inc., a Delaware corporation (“Semnur”) and majority owned subsidiary of Scilex Holding Company (“Scilex”), with Semnur surviving the merger
(the “Business Combination”), copies of each of which are attached to this proxy statement/prospectus as , and , respectively, be and are hereby approved and adopted (such proposal, the
“Business Combination Proposal”). The Business Combination Proposal is conditioned on the approval of the other Condition Precedent Proposals.”

Recommendation of the Denali Board

THE DENALI BOARD UNANIMOUSLY RECOMMENDS THAT DENALI’S SHAREHOLDERS VOTE “FOR” THE APPROVAL OF THE BUSINESS COMBINATION PROPOSAL.

218

THE MERGER AGREEMENT

The following describes the material provisions of the Merger Agreement, but does not purport to describe all of the terms of the Merger Agreement and is subject to, and qualified in its entirety by reference to, the Merger Agreement, including Amendment No. 1 to Merger Agreement and Amendment No. 2 to Merger Agreement, which are attached to this proxy statement/prospectus as Annex A-1, Annex A-